Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag WuXi Biologics and HanchorBio partner to develop and manufacture next-gen fusion proteins for cancer and autoimmune treatments using WuXi’s biologics services.

flag WuXi Biologics and HanchorBio have formed a strategic partnership to develop and manufacture HanchorBio’s next-generation fusion proteins using WuXi’s end-to-end biologics services, including cell line development, process optimization, and GMP manufacturing. flag The collaboration supports HanchorBio’s Fc-Based Designer Biologics platform, aimed at treating cancer and autoimmune diseases by targeting both innate and adaptive immunity. flag WuXi Biologics will leverage its expertise in complex biologics and proprietary platforms to accelerate clinical development and enable scalable, global production. flag As of late 2025, WuXi managed 945 projects, with 60% focused on advanced biologics. flag The partnership emphasizes speed, manufacturing robustness, and global compliance to bring innovative therapies to patients.

12 Articles